Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDETATE CALCIUM DISODIUM vs ADDERALL XR 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
Treatment of acute and chronic lead poisoning (FDA-approved).,Treatment of poisoning by radioactive metals such as plutonium, americium, and curium (off-label).,Treatment of manganese intoxication (off-label).,Treatment of cadmium poisoning (off-label).
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.
10 mg orally once daily in the morning; maximum dose 40 mg/day.
Terminal elimination half-life approximately 1.5-3 hours for the intact chelate; prolonged to 20-40 hours in lead-intoxicated patients due to redistribution of lead from bone.
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
Not metabolized; excreted unchanged in urine, primarily via glomerular filtration.
Amphetamine is primarily metabolized by hepatic CYP2D6 to 4-hydroxyamphetamine, which is further conjugated. Minor pathways include N-dealkylation and deamination. The drug has a half-life of approximately 10-13 hours.
Primarily renal (90-100% as chelated lead complex within 24-48 hours); minimal biliary/fecal excretion (<5%).
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary p H-dependent elimination: acidic p H increases renal clearance, alkaline p H decreases renal clearance; negligible biliary/fecal elimination)
Negligible (<5%); primarily binds lead in extracellular fluid.
15-40% bound to plasma proteins, primarily albumin; lower binding in patients with hepatic impairment
0.3-0.5 L/kg (confined mainly to extracellular space; does not penetrate cells or CNS).
3.0-4.5 L/kg for total amphetamine; high tissue distribution (brain, lungs, kidneys); enters CNS via passive diffusion and active transport
IV or IM: 100% (not absorbed orally).
Oral: quantitative absorption with 90-100% bioavailability of the total amphetamine content; food does not affect overall absorption but may delay peak concentrations with high-fat meals
GFR > 50 m L/min: no adjustment. GFR 30-50 m L/min: reduce dose by 50%. GFR 15-29 m L/min: reduce dose by 75%. GFR < 15 m L/min or dialysis: contraindicated or use with extreme caution at 10-20% of normal dose with monitoring.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: not recommended.
No specific guidelines for Child-Pugh based modifications. Use with caution in severe hepatic impairment due to potential for electrolyte disturbances and nephrotoxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; or 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Course: 5 days, may repeat after 2 days rest. For other indications: weight-based dosing similar to adults (50 mg/kg/day).
Children 6-17 years: starting dose 5 mg once daily; increase by 5 mg weekly based on response; maximum 30 mg/day.
Start at low end of dosing range (e.g., 30-40 mg/kg/day) due to age-related decreased renal function. Monitor renal function and electrolytes closely. Avoid use in patients with pre-existing renal impairment without dose reduction.
Starting dose 5 mg once daily; increase cautiously with monitoring for hypertension, agitation, and cognitive effects.
Black box warning for nephrotoxicity, particularly at high doses; may cause fatal renal failure. Avoid in patients with renal disease unless benefits outweigh risks. Monitor renal function closely during therapy.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Nephrotoxicity - monitor BUN, creatinine, and urinalysis at baseline and during therapy.,Neurotoxicity - may cause tremors, myoclonus, and seizures, especially with high doses.,Hepatotoxicity - monitor liver function tests.,Arrhythmias - may cause QT prolongation; monitor ECG.,Hypocalcemia - monitor serum calcium levels; may cause tetany.,Use with caution in patients with asthma or allergic history.,Not recommended for prophylaxis of heavy metal poisoning.
Serious cardiovascular events, including sudden death in patients with pre-existing structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions (e.g., exacerbation of psychosis, mania, aggression); seizures; serotonin syndrome if combined with serotonergic drugs; long-term growth suppression in children; peripheral vasculopathy including Raynaud's phenomenon; potential for abuse and dependence.
Severe renal disease or anuria.,Acute pancreatitis.,Known hypersensitivity to edetate calcium disodium or any component.,Concurrent use with other nephrotoxic drugs.,Pregnancy (only if clearly needed due to risk to fetus from metal poisoning).
Hypersensitivity to amphetamine or any component of the formulation; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma; agitated states; history of drug abuse; during or within 14 days following MAOI therapy.
No specific food restrictions, but maintain adequate hydration. Avoid alcohol due to potential renal effects.
Take ADDERALL XR with or without food. However, high-fat meals may delay absorption and reduce peak concentrations. Avoid consumption of acidic foods or beverages (e.g., citrus fruits, fruit juices, cola) within 1 hour before or after dosing, as acidity can decrease absorption. Vitamin C (ascorbic acid) and other acidifying agents can reduce efficacy; conversely, alkalizing agents (e.g., antacids, sodium bicarbonate) may potentiate effects.
FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out; potential for teratogenic effects. Second and third trimesters: Potential fetal toxicity from chelation of essential minerals; avoid use unless necessary.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects at high doses. Second trimester: Potential for reduced fetal growth and premature delivery. Third trimester: Risk of neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia) and preterm birth.
It is not known whether edetate calcium disodium is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. No M/P ratio has been reported.
Contraindicated during breastfeeding. Amphetamine is excreted into human milk; M/P ratio approximately 3.5. Infant exposure estimated at 4-8% of maternal weight-adjusted dose. Reported adverse effects in infants include irritability, poor feeding, and sleep disturbances.
Physiologic increases in renal blood flow and glomerular filtration rate during pregnancy may increase clearance of edetate calcium disodium. Pharmacokinetic data are lacking, but dose adjustments may not be required as dosing is typically based on lead levels and renal function. However, careful monitoring of lead levels and renal function is essential. The drug is contraindicated in patients with severe renal impairment.
Increased clearance during 2nd and 3rd trimesters (hepatic induction) may require dose escalation. Postpartum, clearance returns to nonpregnant levels, requiring dose reduction to avoid toxicity. Individualize dosing based on clinical response and tolerability.
Edetate calcium disodium is used for chelation therapy in heavy metal poisoning, particularly lead. Monitor renal function closely due to risk of nephrotoxicity. Administer via slow IV infusion (over 8-12 hours) after dilution to minimize irritation. Contraindicated in anuria or severe renal impairment. Rapid infusion may cause hypocalcemic tetany; ensure adequate hydration to enhance lead excretion. Use with caution in patients with arrhythmias due to potential electrolyte disturbances.
ADDERALL XR (mixed amphetamine salts extended-release) 10 mg is a CNS stimulant indicated for ADHD. Initiate at 10 mg once daily in the morning; titrate in 5-10 mg increments weekly. Swallow capsules whole, or sprinkle contents on applesauce for patients unable to swallow. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Abuse potential is high; use with caution in patients with history of substance abuse. Contraindicated in glaucoma, hyperthyroidism, agitated states, MAOI use within 14 days, and structural cardiac abnormalities.
This medication is used to remove lead from your body.,You will receive this drug as an intravenous infusion over several hours.,Drink plenty of fluids during treatment to help flush out lead.,Report any muscle cramps, numbness, or tingling immediately.,Your kidney function and electrolyte levels will be monitored during treatment.,Avoid taking other medications without consulting your doctor, especially those affecting the kidneys.
Take exactly as prescribed once daily in the morning with or without food.,Do not chew or crush the capsule; you may open it and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing.,Avoid taking in the afternoon or evening as it may cause difficulty sleeping.,Do not stop abruptly without consulting your doctor; sudden discontinuation may cause withdrawal symptoms.,Report any chest pain, palpitations, shortness of breath, or fainting to your doctor.,This medication has a high potential for abuse; keep in a safe place and do not share with others.,Avoid alcohol and illicit drugs while taking this medication.,Notify your doctor if you have a history of drug dependence, anxiety, bipolar disorder, or seizures.,For patients with ADHD, it may improve focus, attention, and impulse control.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDETATE CALCIUM DISODIUM vs ADDERALL XR 10, answered by our medical review team.
EDETATE CALCIUM DISODIUM is a Chelating Agent that works by Chelates heavy metals (e.g., lead, cadmium) by forming stable complexes with divalent and trivalent cations, which are then excreted in urine.. ADDERALL XR 10 is a CNS Stimulant that works by Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDETATE CALCIUM DISODIUM and ADDERALL XR 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDETATE CALCIUM DISODIUM is: Edetate calcium disodium is administered intravenously or intramuscularly. For lead poisoning: 1000 mg/m²/day IV continuous infusion or in divided doses every 12 hours; alternatively 50 mg/kg/day IV or IM in divided doses every 8-12 hours. Maximum 3000 mg/day. Duration typically 5 days, repeat after 2 days rest. For other heavy metal toxicity: 50 mg/kg/day IV or IM in divided doses every 8-12 hours for 3-5 days.. The standard adult dose of ADDERALL XR 10 is: 10 mg orally once daily in the morning; maximum dose 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDETATE CALCIUM DISODIUM and ADDERALL XR 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDETATE CALCIUM DISODIUM is classified as Category C. FDA Pregnancy Category C. In animal studies, edetate calcium disodium has been shown to be teratogenic (skeletal anomalies) at doses approximately 0.25 times the human dose. There . ADDERALL XR 10 is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.